Michael S Isakoff1, Robert Goldsby2, Doojduen Villaluna3, Mark D Krailo3,4, Pooja Hingorani5, Anderson Collier6, Carol D Morris7, E Anders Kolb8, John J Doski9, Richard B Womer10, Richard Gorlick11, Katherine A Janeway12. 1. Center for Cancer and Blood Disorders, Connecticut Children's Medical Center, Hartford, Connecticut. 2. Division of Pediatric Hematology/Oncology, University of California San Francisco, Benioff Children's Hospital, San Francisco, California. 3. Children's Oncology Group, Monrovia, California. 4. Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California. 5. Center for Cancer and Blood Disorders, Phoenix Children's Hospital, Phoenix, Arizona. 6. Hematology/Oncology, University of Mississippi Medical Center, Jackson, Mississippi. 7. Division of Orthopaedic Oncology, John Hopkins Medicine, Baltimore, Maryland. 8. Alfred I DuPont Hospital for Children, Wilmington, Delaware. 9. Department of Surgery/Pediatric Surgery Division, University of Texas Health Science Center, San Rosa Children's Hospital, San Antonio, Texas. 10. Division of Oncology, The Children's Hospital of Philadelphia, University of Pennsylvania, Philadelphia, Pennsylvania. 11. Division of Pediatrics, The University of Texas, MD Anderson Cancer Center, Baltimore, Maryland. 12. Department of Pediatric Oncology, Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, Massachusetts.
Abstract
BACKGROUND: Patients with recurrent or refractory osteosarcoma have a poor prognosis with less than 30% surviving two years. Eribulin is a synthetic analog of halichondrin B, has a novel mechanism of action when compared with other microtubule inhibitors, and may have antitumor activity in osteosarcoma. METHODS: A prospective study was designed to assess the disease control success at four months and objective response rates in patients with recurrent or refractory osteosarcoma treated with eribulin. Eligible patients were between 12 and 50 years of age, had measurable tumor, and met standard organ function requirements. Patients were given eribulin 1.4 mg/m2 /dose on days 1 and 8 of each 3-week cycle for up to 24 months if there was no progressive disease. Response to therapy was assessed using RECIST 1.1 criteria after cycles 2 and 5 and every fourth cycle thereafter. RESULTS: Nineteen patients enrolled on the AOST1322 study. The median age of enrollment was 16 years (range, 12-25 years). Twelve patients were male and seven female. Eribulin was well tolerated, with neutropenia identified as the most common toxicity. The median progression-free survival was 38 days and no patients reached the four-month time point without progression. No objective responses were seen in any patient. CONCLUSION: This study rapidly assessed the clinical activity of a novel agent in this patient population. Eribulin was well tolerated, but there were no patients who demonstrated objective response, and all patients had progression prior to four months.
BACKGROUND:Patients with recurrent or refractory osteosarcoma have a poor prognosis with less than 30% surviving two years. Eribulin is a synthetic analog of halichondrin B, has a novel mechanism of action when compared with other microtubule inhibitors, and may have antitumor activity in osteosarcoma. METHODS: A prospective study was designed to assess the disease control success at four months and objective response rates in patients with recurrent or refractory osteosarcoma treated with eribulin. Eligible patients were between 12 and 50 years of age, had measurable tumor, and met standard organ function requirements. Patients were given eribulin 1.4 mg/m2 /dose on days 1 and 8 of each 3-week cycle for up to 24 months if there was no progressive disease. Response to therapy was assessed using RECIST 1.1 criteria after cycles 2 and 5 and every fourth cycle thereafter. RESULTS: Nineteen patients enrolled on the AOST1322 study. The median age of enrollment was 16 years (range, 12-25 years). Twelve patients were male and seven female. Eribulin was well tolerated, with neutropenia identified as the most common toxicity. The median progression-free survival was 38 days and no patients reached the four-month time point without progression. No objective responses were seen in any patient. CONCLUSION: This study rapidly assessed the clinical activity of a novel agent in this patient population. Eribulin was well tolerated, but there were no patients who demonstrated objective response, and all patients had progression prior to four months.
Authors: Patrick Schöffski; Isabelle Laure Ray-Coquard; Angela Cioffi; Nguyen Bin Bui; Sebastian Bauer; Joerg Thomas Hartmann; Anders Krarup-Hansen; Viktor Grünwald; Raf Sciot; Herlinde Dumez; Jean-Yves Blay; Axel Le Cesne; Jantien Wanders; Carolyn Hayward; Sandrine Marreaud; Monia Ouali; Peter Hohenberger Journal: Lancet Oncol Date: 2011-09-19 Impact factor: 41.316
Authors: Peter J Houghton; Christopher L Morton; Chandra Tucker; Debbie Payne; Edward Favours; Claire Cole; Richard Gorlick; E Anders Kolb; Wendong Zhang; Richard Lock; Hernan Carol; Mimi Tajbakhsh; C Patrick Reynolds; John M Maris; Joshua Courtright; Stephen T Keir; Henry S Friedman; Charles Stopford; Joseph Zeidner; Jianrong Wu; Tiebin Liu; Catherine A Billups; Javed Khan; Sherry Ansher; Jian Zhang; Malcolm A Smith Journal: Pediatr Blood Cancer Date: 2007-12 Impact factor: 3.167
Authors: Patrick Schöffski; Sant Chawla; Robert G Maki; Antoine Italiano; Hans Gelderblom; Edwin Choy; Giovanni Grignani; Veridiana Camargo; Sebastian Bauer; Sun Young Rha; Jean-Yves Blay; Peter Hohenberger; David D'Adamo; Matthew Guo; Bartosz Chmielowski; Axel Le Cesne; George D Demetri; Shreyaskumar R Patel Journal: Lancet Date: 2016-02-10 Impact factor: 79.321
Authors: Malcolm A Smith; Nita L Seibel; Sean F Altekruse; Lynn A G Ries; Danielle L Melbert; Maura O'Leary; Franklin O Smith; Gregory H Reaman Journal: J Clin Oncol Date: 2010-04-19 Impact factor: 44.544
Authors: Chand Khanna; Timothy M Fan; Richard Gorlick; Lee J Helman; Eugenie S Kleinerman; Peter C Adamson; Peter J Houghton; William D Tap; Danny R Welch; Patricia S Steeg; Glenn Merlino; Poul H B Sorensen; Paul Meltzer; David G Kirsch; Katherine A Janeway; Brenda Weigel; Lor Randall; Stephen J Withrow; Melissa Paoloni; Rosandra Kaplan; Beverly A Teicher; Nita L Seibel; Malcolm Smith; Aykut Uren; Shreyaskumar R Patel; Jeffrey Trent; Sharon A Savage; Lisa Mirabello; Denise Reinke; Donald A Barkaukas; Mark Krailo; Mark Bernstein Journal: Clin Cancer Res Date: 2014-05-06 Impact factor: 12.531
Authors: George D Demetri; Patrick Schöffski; Giovanni Grignani; Jean-Yves Blay; Robert G Maki; Brian A Van Tine; Thierry Alcindor; Robin L Jones; David R D'Adamo; Matthew Guo; Sant Chawla Journal: J Clin Oncol Date: 2017-08-30 Impact factor: 44.544
Authors: Ryan D Roberts; Michael M Lizardo; Damon R Reed; Pooja Hingorani; Jason Glover; Wendy Allen-Rhoades; Timothy Fan; Chand Khanna; E Alejandro Sweet-Cordero; Thomas Cash; Michael W Bishop; Meenakshi Hegde; Aparna R Sertil; Christian Koelsche; Lisa Mirabello; David Malkin; Poul H Sorensen; Paul S Meltzer; Katherine A Janeway; Richard Gorlick; Brian D Crompton Journal: Cancer Date: 2019-07-29 Impact factor: 6.860
Authors: Fiorela N Hernandez Tejada; Alejandro Zamudio; Mario L Marques-Piubelli; Branko Cuglievan; Douglas Harrison Journal: Curr Oncol Rep Date: 2020-11-16 Impact factor: 5.075
Authors: Lisa M Kopp; Suman Malempati; Mark Krailo; Yun Gao; Allen Buxton; Brenda J Weigel; Thomas Hawthorne; Elizabeth Crowley; Jeffrey A Moscow; Joel M Reid; Victor Villalobos; R Lor Randall; Richard Gorlick; Katherine A Janeway Journal: Eur J Cancer Date: 2019-10-03 Impact factor: 9.162
Authors: Jonathan Gill; Wendong Zhang; Zhongting Zhang; Michael Roth; Douglas J Harrison; Sudie Rowshan; Stephen Erickson; Gregory Gatto; Raushan Kurmasheva; Peter Houghton; Beverly Teicher; Malcolm A Smith; E Anders Kolb; Richard Gorlick Journal: Pediatr Blood Cancer Date: 2020-07-24 Impact factor: 3.167
Authors: Holly L Pacenta; Wendy Allen-Rhoades; David Langenau; Peter J Houghton; Charles Keller; Christine M Heske; Michael D Deel; Corinne M Linardic; Jack F Shern; Elizabeth Stewart; Brian Turpin; Douglas J Harrison; Javed Khan; Leo Mascarenhas; Stephen X Skapek; William H Meyer; Douglas S Hawkins; Eleanor Y Chen; James F Amatruda; Pooja Hingorani; Theodore W Laetsch Journal: J Clin Med Date: 2021-04-01 Impact factor: 4.241
Authors: Sarah B Whittle; Katharine Offer; Ryan D Roberts; Amy LeBlanc; Cheryl London; Robbie G Majzner; Alex Y Huang; Peter Houghton; E Alejandro Sweet Cordero; Patrick J Grohar; Michael Isakoff; Michael W Bishop; Elizabeth Stewart; Emily K Slotkin; Emily Greengard; Scott C Borinstein; Fariba Navid; Richard Gorlick; Katherine A Janeway; Damon R Reed; Pooja Hingorani Journal: Pediatr Blood Cancer Date: 2021-06-16 Impact factor: 3.838